Brian D. Koh - Concepedia

Author

Brian D. Koh

Sidney Kimmel Comprehensive Cancer Center ORCID

Also Known As

B Koh, B. D. Koh, BRIAN KOH, Brian D Koh, Brian D. Koh, Brian Koh

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Sidney Kimmel Comprehensive Cancer Center Yale University Mayo Clinic Sidney Kimmel Cancer Center Dana-Farber Cancer Institute

About

Brian D. Koh is an author at Sidney Kimmel Comprehensive Cancer Center specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	772
2	Cell Biology	3	3	242
3	Engineering	2	2	132
4	Natural Sciences	1	1	14
5	Biochemistry	1	1	14

Brian D. Koh

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase Benjamin H. Kwok, Brian D. Koh, MacKevin Ndubuisi, Chemistry & Biology InflammationCytokineAnti-inflammatoryMedicineInhibits Iκb Kinase	2001	506
Linking gene expression patterns to therapeutic groups in breast cancer. Katherine J. Martin, Brian M. Kritzman, Lorne M. Price, PubMed Breast OncologyEngineeringCluster AnalysisCancer BiologyGene Expression Profiling	2000	122
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, Blood	2011	102
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Haematologica Wee1 KinaseTumor BiologyHematological MalignancyDna Repair GenesMixed-phenotype Acute Leukemia	2013	76
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression X. Wei Meng, Brian D. Koh, Jin‐San Zhang, Journal of Biological Chemistry	2014	60
Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i> Erin L. Schenk, Brian D. Koh, Karen S. Flatten, Clinical Cancer Research	2012	54
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells Husheng Ding, Kevin L. Peterson, Cristina Correia, Leukemia Tumor BiologyLymphoid NeoplasiaOncologyEpigenetic RegulationMedicine	2016	44
Total Synthesis of Luminacin D J. Brad Shotwell, Evan S. Krygowski, John Hines, Organic Letters	2002	42
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma Kimmie Ng, Andrew Hendifar, Alexander Starodub, Investigational New Drugs	2018	34
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms Keith W. Pratz, Brian D. Koh, Anand G. Patel, Clinical Cancer Research	2016	25

Page 1